MedJ takes you straight to ASCO 2025.
Professor Kohei Shitara from Japan's National Cancer Center reported the global Phase III breakthrough of trastuzumab deruxtecan in treating HER2-positive gastric cancer at the 2025 ASCO Annual Meeting.
MedJ takes you straight to ASCO 2025.
Professor Kohei Shitara from Japan's National Cancer Center reported the global Phase III breakthrough of trastuzumab deruxtecan in treating HER2-positive gastric cancer at the 2025 ASCO Annual Meeting.